LENZ Taps Everest for China Commercialization, Sets Q1 2027 Approval Target

What happened

LENZ Therapeutics announced that Everest Medicines has acquired rights to develop and commercialize VIZZ (LNZ100) in Greater China, with the NDA submitted in September 2025 and approval anticipated in Q1 2027. This replaces or supplements the prior CORXEL partnership and provides a clearer path to monetizing the Chinese market, though deal terms were undisclosed. The news reduces LENZ's single-market dependency but does little to de-risk the core U.S. commercial trajectory, where Q4 2025 net product revenue was ~$1.6M and the DTC campaign launched in January 2026 has yet to show acceleration. The China deal adds a credible partner with deep regional expertise, but financial impact is likely back-end loaded, with milestones only after approval. Overall, the partnership is a positive for ex-U.S. optionality but does not alter the binary nature of the U.S. launch ramp.

Implication

Everest Medicines' acquisition of China rights for VIZZ is a positive signal for ex-U.S. monetization, adding a credible partner with deep regional expertise. However, the financial impact is likely back-end loaded, with milestones only after approval (Q1 2027). Meanwhile, LENZ's U.S. commercial execution remains unproven; the Q1 2026 results, expected soon, will test whether the DTC spend is driving prescription growth. Without a clear sequential revenue acceleration from the Q4 2025 baseline, the stock will struggle to hold above cash-equivalent valuations. The partnership does not change the bear case: safety overhang and weak persistence could still cap adoption. Maintain a cautious stance until U.S. revenue trends become visible.

Thesis delta

Previously, the thesis relied on U.S. ramp and the optionality of ex-U.S. partnerships with uncertain milestone timing. The Everest deal crystallizes a specific China approval timeline (Q1 2027) and introduces a potentially stronger partner, reducing some risk around the China optionality. However, the core investment case still hinges on U.S. demand acceleration in the next two quarters; the China deal does not alter that binary.